267 related articles for article (PubMed ID: 35131861)
1. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
[TBL] [Abstract][Full Text] [Related]
2. Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction.
Mostböck S; Wu HH; Fenn T; Riegler B; Strahlhofer S; Huang Y; Hansen G; Kroe-Barrett R; Tirapu I; Vogt AB
Front Immunol; 2022; 13():862757. PubMed ID: 35967294
[TBL] [Abstract][Full Text] [Related]
3. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
[TBL] [Abstract][Full Text] [Related]
4. Correction: Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35185007
[No Abstract] [Full Text] [Related]
5. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
[TBL] [Abstract][Full Text] [Related]
7. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.
Wakiyama H; Furusawa A; Okada R; Inagaki F; Kato T; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
Cancer Immunol Immunother; 2022 Dec; 71(12):2869-2879. PubMed ID: 35445836
[TBL] [Abstract][Full Text] [Related]
8. VISTA Regulates the Development of Protective Antitumor Immunity.
Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L
Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994
[TBL] [Abstract][Full Text] [Related]
9. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma.
Liu J; Lin WP; Xiao Y; Yang QC; Bushabu Fidele N; Yu HJ; Sun ZJ
Int Immunopharmacol; 2023 Dec; 125(Pt A):111128. PubMed ID: 37907049
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.
Wang L; Le Mercier I; Putra J; Chen W; Liu J; Schenk AD; Nowak EC; Suriawinata AA; Li J; Noelle RJ
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14846-51. PubMed ID: 25267631
[TBL] [Abstract][Full Text] [Related]
11. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
[TBL] [Abstract][Full Text] [Related]
12. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance.
Schaafsma E; Croteau W; ElTanbouly M; Nowak EC; Smits NC; Deng J; Sarde A; Webber CA; Rabadi D; Cheng C; Noelle R; Lines JL
Cancer Immunol Res; 2023 Jan; 11(1):38-55. PubMed ID: 36260656
[TBL] [Abstract][Full Text] [Related]
13. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L; Tatineni J; Mahoney KM; Freeman GJ
Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models.
Duval KEA; Tavakkoli AD; Kheirollah A; Soderholm HE; Demidenko E; Lines JL; Croteau W; Zhang SC; Wagner RJ; Aulwes E; Noelle RJ; Hoopes PJ
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762046
[TBL] [Abstract][Full Text] [Related]
15. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
Lines JL; Sempere LF; Broughton T; Wang L; Noelle R
Cancer Immunol Res; 2014 Jun; 2(6):510-7. PubMed ID: 24894088
[TBL] [Abstract][Full Text] [Related]
16. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
[TBL] [Abstract][Full Text] [Related]
17. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
Mortezaee K; Majidpoor J; Najafi S
Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
[TBL] [Abstract][Full Text] [Related]
18. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.
Mehta N; Maddineni S; Kelly RL; Lee RB; Hunter SA; Silberstein JL; Parra Sperberg RA; Miller CL; Rabe A; Labanieh L; Cochran JR
Sci Rep; 2020 Sep; 10(1):15171. PubMed ID: 32938950
[TBL] [Abstract][Full Text] [Related]
19. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
20. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
